MREO Mereo BioPharma Group plc American Depositary Shares Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
17:48
Jan 16
Jan 16
MREO recovery bet on cash runway and alvelestat pipeline
The author holds and modestly added to MREO after the setrusumab Phase 3 miss, arguing the negative news is largely priced in at current levels. The mechanism is a remaining pipeline, especially alvelestat advancing toward a single global Phase 3 for AATD-associated lung disease, plus cash and equivalents of about $41 million as of Dec. 31, 2025 extending runway into mid-2027. The author notes the company is engaging regulators on next steps for setrusumab after positive bone mineral density data. Stated risks include regulatory hurdles, further trial setbacks, or dilution that could drive shares to zero.
MED
13:39
Jan 14
Jan 14
MREO cheap with cash runway and pipeline
The author argues MREO is cheap at about $0.70 after being wrecked but climbing, supported by cash lasting to mid-2027, no big debt, and another drug in the works. The mechanism is a low valuation relative to analyst targets around 3x, with the catalyst being continued pipeline progress. The main stated risk is framed as gambling on the stock.
HIGH
About MREO Investor Commentary
Across the available history and selected sources, Buzzberg tracks MREO (Mereo BioPharma Group plc American Depositary Shares) across 1 sources: 2 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: u/saga273.